The new process developed by Rice University researchers makes solar cells that are about 10 times more durable than traditional methods. Photos by Jeff Fitlow/Rice University

A groundbreaking Rice University lab has made further strides in its work to make harvesting light energy more efficient and stable.

Presented on the cover of a June issue of Science, a study from Rice engineer Aditya Mohite's lab uncovered a method to synthesize a high-efficiency perovskite solar cell, known as formamidinium lead iodide (FAPbI3), converting them into ultrastable high-quality photovoltaic films, according to a statement from Rice. Photovoltaic films convert sunlight into electricity.

The new process makes solar cells that are about 10 times more durable than traditional methods.

“Right now, we think that this is state of the art in terms of stability,” Mohite said in a statement. “Perovskite solar cells have the potential to revolutionize energy production, but achieving long-duration stability has been a significant challenge.”

The change come from "seasoning" the FAPbI3 with 2D halide perovskites crystals, which the Mohite lab also developed a breakthrough synthesis process for last year

The 2D perovskites helped make the FAPbI3 films more stable. The study showed that films with 2D perovskites deteriorated after two days of generating electricity, while those with 2D perovskites had not started to degrade after 20 days.

“FAPbI3 films templated with 2D crystals were higher quality, showing less internal disorder and exhibiting a stronger response to illumination, which translated as higher efficiency," Isaac Metcalf, a Rice materials science and nanoengineering graduate student and a lead author on the study, said in the statement.

Additionally, researchers say their findings could make developing light-harvesting technologies cheaper, and can also allow light-harvesting panels to be lighter weight and more flexible.

"Perovskites are soluble in solution, so you can take an ink of a perovskite precursor and spread it across a piece of glass, then heat it up and you have the absorber layer for a solar cell,” Metcalf said. “Since you don’t need very high temperatures ⎯ perovskite films can be processed at temperatures below 150 Celsius (302 Fahrenheit) ⎯ in theory that also means perovskite solar panels can be made on plastic or even flexible substrates, which could further reduce costs.”

Mohite adds this has major implications for the energy transition at large.

“If solar electricity doesn’t happen, none of the other processes that rely on green electrons from the grid, such as thermochemical or electrochemical processes for chemical manufacturing, will happen,” Mohite said. “Photovoltaics are absolutely critical.”

The Mohite lab's process for creating 2D perovskites of the ideal thickness and purity was published in Nature Synthesis last fall. At the time, Mohite said the crystals "hold the key to achieving commercially relevant stability for solar cells."

About a year ago, the lab also published its work on developing a scalable photoelectrochemical cell. The research broke records for its solar-to-hydrogen conversion efficiency rate.

———

This article originally ran on EnergyCapital.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.